Immatics enters I-O research collaboration with Genmab

Privately-held German firm Immatics Biotechnologies has entered into a research collaboration and license agreement with Danish biotech firm Genmab (OMX: GEN) to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.

The companies will conduct joint research, funded by Genmab, to combine Immatics’ XPRESIDENT and Bispecific TCR technology platforms with Genmab’s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. The companies will exclusively discover and develop immunotherapies directed against three proprietary targets, which were discovered and developed by Immatics’ XPRESIDENT technology. Genmab has the option to exclusively license up to two additional targets to expand the partnership at predetermined economics.

Genmab, whose shares were up 1.5% at 1,071.50 Danish kroner late morning, will be responsible for development, manufacturing and worldwide commercialization. Immatics will have an option to contribute certain promotion efforts at predetermined levels in selected countries in the European Union.